Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 15, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions and does not contain financial performance data.
Material Changes
- Employee Share Option Plan: On March 14, 2005, the GlaxoSmithKline Employee Trust transferred 4,552 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- US Retirement Savings Plan: On March 11, 2005, the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan increased from 18,253,506 to 18,472,029 at an average price of $48.60.
- Director Notional Allocation: Following a re-valuation of the cash element within the US Retirement Savings Plan, Dr. T Yamada received an increase in the notional allocation of Ordinary Share ADRs on March 11, 2005, at a price of $48.48 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a routine disclosure of director interests and does not contain forward-looking statements or risk assessments.
Investor Verification Points
- Verify the impact of the 4,552 share transfer from the GSK Trust on the total outstanding share count.
- Confirm the total number of ADRs held by the US Retirement Savings Plan (18,472,029) and the associated directors' potential interests.
- Note the specific directors with interests in these plans: Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe (GSK Trust); Dr. J-P Garnier and Dr. T Yamada (US Retirement Savings Plan).